Get it on Google Play

Axogen receives FDA approval for AVANCE nerve allograft biologics license

December 3, 2025 8:01 PM EST Send to a Friend
Axogen Inc. (NASDAQ: AXGN) announced that the U.S. Food and Drug Administration has approved its Biologics License Application for AVANCE ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login